Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

Nuvation Bio Inc. has announced the pricing of its underwritten offering of $250 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032. This offering size was increased from a previously announced $200 million, reflecting strong investor demand. The sale of the notes is expected to close on June 30, 2026, subject to customary closing conditions. The net proceeds from this offering are estimated to be approximately $241.2 million, which will be allocated for capped call transactions, repayment of a senior secured loan, and general corporate purposes.

Nuvation Bio, which trades on the New York Stock Exchange under the ticker NUVB, is a global oncology company dedicated to addressing significant challenges in cancer treatment. The company is focused on developing innovative therapies and has a pipeline that includes various drug candidates aimed at improving patient outcomes in oncology. The decision to increase the offering size indicates a robust interest from investors, likely driven by the company's strategic position within the oncology sector, which has seen increasing investment and innovation in recent years.

The 0.75% Convertible Senior Notes will accrue interest payable semiannually, with the first payment scheduled for January 1, 2027. The notes will mature on July 1, 2032, unless converted, redeemed, or repurchased earlier. Investors will have the option to convert their notes into shares of Nuvation Bio's Class A common stock, with an initial conversion rate set at approximately 127.4941 shares per $1,000 principal amount of notes, which represents a conversion premium of about 35% over the last reported sale price of the stock. This feature provides an attractive opportunity for investors, particularly in a sector characterized by high growth potential.

The proceeds from this offering will not only facilitate the repayment of existing debt but also support Nuvation Bio's ongoing operational needs and strategic initiatives. The capped call transactions associated with the offering are designed to mitigate potential dilution from the conversion of the notes, which is a common strategy among companies looking to balance capital needs with shareholder interests. This move underscores Nuvation Bio's commitment to maintaining a strong capital structure while pursuing its growth objectives in the competitive oncology landscape.

The broader market for oncology investments remains robust, with increasing interest from both institutional and retail investors. The growing prevalence of cancer and advancements in treatment modalities are driving demand for innovative therapies. As Nuvation Bio continues to develop its pipeline, the successful completion of this fundraise positions the company to capitalize on market opportunities and enhance its competitive edge in the oncology sector. The strategic use of proceeds from the offering will play a critical role in supporting the company's long-term vision and operational strategies in this dynamic market environment.